«上一篇/Previous Article|本期目录/Table of Contents|下一篇/Next Article»

《天津医科大学学报》[ISSN:1006-8147/CN:12-1259/R]

卷:

25卷

期数:

2019年04期

页码:

346-350

栏目:

临床医学

出版日期:

2019-07-20

文章信息/Info

Title:

The effectiveness of CyberKnife for brain metastases from small cell lung cancer

文章编号:

1006-8147(2019)04-0346-05

作者:

赵军华¹; 邱鸣寒²; 袁智勇¹

（1天津医科大学肿瘤医院放疗科射波刀中心 ，国家肿瘤临床医学研究中心 ，天津市“肿瘤防治”重点实验室，天津市恶性肿瘤临床医学研究中心，天津 300060；2天津市人民医院肿瘤内科，天津 300121）

Author(s):

ZHAO Jun-hua¹;  QIU Ming-han²;  YUAN Zhi-yong¹

(1 Department of Radiation Oncology and CyberKnife Center, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin Key Lanboratory of Cancer Prevention and Therapy, Tianjin’s Clinical Research Center for Cancer, Tianjin 300060 China; 2 Department of Medical Oncology, Tianjin People’s Hospital, Tianjin 300121, China)

关键词:

小细胞肺癌; 脑转移瘤; 全脑放疗; 射波刀立体定向放射外科; 生存

Keywords:

small cell lung cancer;  brain metastases;  whole brain radiotherapy;  stereotactic radiosurgery;  overall survival

分类号:

R730.55

DOI:

-

文献标志码:

A

摘要:

目的：探讨射波刀立体定向放射外科（SRS）治疗小细胞肺癌（SCLC）脑转移（BM）的有效性及安全性。方法：回顾性分析2006年7月-2015年12月期间SRS 治疗的28例SCLC脑转移的患者资料，其中包括全脑放疗（WBRT）与SRS联合治疗 13例，SRS挽救性治疗15例。分析总生存时间（OS）、颅内局部控制率（LC）及颅内无远处转移生存（DMFS）情况。结果：中位随访时间为13个月，中位生存期为12个月，1年、2年的OS分别为50.0%、22.2%；1年、2年的LC分别为85.4%、76.8%； 6个月、1年、2年的DMFS为73.9%、66.1%、38.2%。治疗后1.5月内，1~2级急性毒副反应发生率为10%，未见3级及3级以上急性毒副反应。结论：SRS治疗SCLC脑转移患者可取得较好的生存率，并且不良反应少，是安全有效的方法。

Abstract:

Objective: To evaluate the efficacy and safety of CyberKnife stereotactic radiosurgery(SRS) in the treatment of patients with brain metastases (BM) from small cell lung cancer(SCLC). Methods: A group of 28 patients with brain metastases from small cell lung cancer treated with CyberKnife SRS from July 2006 to December 2015 were retrospectively studied. There were 13 cases of whole brain radiotherapy(WBRT) combined with stereotactic radiosurgery and 15 cases of salvage stereotactic radiosurgery therapy. Overall survival (OS), Local contral(LC) and Distant metastases free survival(DMFS) were analyzed to assess the efficacy. Results: In a median follow-up of 13 months, the median overall survival was 12 months, 1-and 2-year overall survivals were 50.0% and 22.2%; 1-and 2-year local contral were 85.4% and 76.8%, respectively; the median time for distant metastases was 6 months, 1-and 2-year distant metastases free survivals were 66.1% and 38.2%. Within 1.5 months after treatment, the incidence of acute toxic and side effects of grade 1-2 was 10%, and no acute side effects of grade 3 or higher were observed. Conclusion: CyberKnife SRS can achieve higher survival rate and less adverse reactions in the treatment of SCLC brain metastasis, and it may be a safe and effective method.

参考文献/References:

[1] Seute T, Leffers P, ten Velde G P, et al. Neurologic disorders in 432 consecutive patients with small cell lung carcinoma[J]. Cancer, 2004, 100(4): 801
[2] Slotman B, Faivrefinn C, Kramer G, et al. Prophylactic cranial irradiation in extensive small-cell lung cancer-NEJM[J]. N Engl J Med, 2007, 357(7): 664
[3] Ramlov A, Tietze A, Khalil A A, et al. Prophylactic cranial irradiation in patients with small cell lung cancer. A retrospective study of recurrence, survival and morbidity [J]. Lung cancer, 2012, 77(3): 561
[4] Aoyama H, Shirato H, Tago M, et al. Stereotactic radiosurgery plus whole-brain radiation therapy vs stereotactic radiosurgery alone for treatment of brain metastases: a randomized controlled trial[J]. JAMA, 2006, 295(21): 2483
[5] Harris S, Chan M D, Lovato J F, et al. Gamma knife stereotactic radiosurgery as salvage therapy after failure of whole-brain radiotherapy in patients with small-cell lung cancer[J]. Int J Radiat Oncol Biol Phys, 2012, 83(1): e53
[6] Olson A C,Wegner R E, Rwigema J C et al. Clinical outcomes of reirradiation of brain metastases from small cell lung cancer with Cyberknife stereotactic radiosurgery[J]. J Cancer Res Ther, 2012, 8(3):411
[7] Nakazaki K, Higuchi Y, Nagano O, et al. Efficacy and limitations of salvage gamma knife radiosurgery for brain metastases of small-cell lung cancer after whole-brain radiotherapy[J]. Acta Neurochir, 2013, 155(1): 107
[8] Yomo S, Hayashi M. Is stereotactic radiosurgery a rational treatment option for brain metastases from small cell lung cancer? A retrospective analysis of 70 consecutive patients[J]. BMC Cancer, 2015, 15(1):1
[9] Robin T P, Jones B L, Amini A, et al. Radiosurgery alone is associated with favorable outcomes for brain metastases from small-cell lung cancer[J].Lung Cancer, 2018, 120: 88
[10] Sperduto P W, Berkey B, Gaspar L E, et al. A new prognostic index and comparison to three other indices for patients with brain metastases: an analysis of 1,960 patients in the RTOG database[J]. Int J Radiat Oncol Biol Phys, 2008, 70(2): 510
[11] Seute T, Leffers P, ten Velde G P, et al. Detection of brain metastases from small cell lung cancer: consequences of changing imaging techniques (CT versus MRI)[J]. Cancer, 2008, 112(8): 1827
[12] Ozawa Y, Omae M, Fujii M, et al. Management of brain metastasis with magnetic resonance imaging and stereotactic irradiation attenuated benefits of prophylactic cranial irradiation in patients with limited-stage small cell lung cancer [J]. BMC Cancer, 2015, 15(1): 589
[13] Takahashi T, Yamanaka T, Seto T, et al. Prophylactic cranial irradiation versus observation in patients with extensive-disease small-cell lung cancer: a multicentre, randomised, open-label, phase 3 trial[J]. Lancet Oncol, 2017, 18(5): 663
[14] Mamesaya N, Wakuda K, Omae K, et al. Efficacy of prophylactic cranial irradiation in patients with limited-disease small-cell lung cancer who were confirmed to have no brain metastasis via magnetic resonance imaging after initial chemo-radiotherapy[J]. Oncotarget,2018, 9(25): 17664
[15] Kawabe T P J, Yamamoto M, Kim D G. Treatment of brain metastasis from lung cancer[J]. Prog Neurol Surg, 2012, 25(2):148
[16] Laukkanen E, Klonoff H, Allan B, et al. The role of prophylactic brain irradiation in limited stage small cell lung cancer: clinical, neuropsychologic, and CT sequelae[J]. Int J Radiat Oncol Biol Phys, 1988, 14(6): 1109
[17] Gondi V, Pugh S L, Tome W A, et al. Preservation of memory with conformal avoidance of the hippocampal neural stem-cell compartment during whole-brain radiotherapy for brain metastases (RTOG 0933): a phase II multi-institutional trial[J]. J Clin Oncol, 2014, 32(34): 3810
[18] Kirakli E K, Oztekin O. Is Hippocampal avoidance during whole-brain radiotherapy risky for patients with small-cell lung cancer? hippocampal metastasis rate and associated risk factors[J].Technol Cancer Res Treat, 2017, 16(6):1202
[19] 郭艺航,庄洪卿,袁智勇,等. 射波刀治疗后放射性脑坏死影响因素及其预测因子研究[J]. 中华放射肿瘤学杂志, 2015, 24(3):295

相似文献/References:

[1]李家腾,宋世辉,王 田,等.小细胞肺癌患者化疗前后CEA、NSE和CYFRA21-1的变化对评估预后的作用[J].天津医科大学学报,2014,20(06):448.
　LI Jia-teng,SONG Shi-hui,WANG Tian,et al.Effect of Changes of CEA, NSE and CYFRA21-1 before and after chemotherapy on the evaluation of prognosis in patients with small cell lung cancer[J].Journal of Tianjin Medical University,2014,20(04):448.
[2]殷小会,郭 慧,马 慧,等.增强T1-FLAIR与3D-FSPGR序列对脑转移瘤检出率对比研究[J].天津医科大学学报,2016,22(05):434.
　YIN Xiao-hui,GUO Hui,MA Hui,et al.Comparative study?on contrast -enhanced? T1-FLAIR and 3D-FSPGR sequences in detection of brain metastasis[J].Journal of Tianjin Medical University,2016,22(04):434.
[3]王子乔,张雪茜,孟凡荣,等.小鼠小细胞肺癌模型的建立[J].天津医科大学学报,2018,24(01):29.
　WANG Zi-qiao,ZHANG Xue-xi,MENG Fan-rong,et al.Establishment of a mouse model of pulmonary small cell lung cancer[J].Journal of Tianjin Medical University,2018,24(04):29.
[4]张姝阳,张家丽,赵 宁,等.IP方案与CAO方案二线治疗复发小细胞肺癌的疗效及毒副作用比较研究[J].天津医科大学学报,2018,24(05):415.
　ZHANG Shu-yang,ZHANG Jia-li,ZHAO Ning,et al.Comparison of the efficacy and toxicity between the IP regimen and the CAO regimen in the second line treatment for recurrent small cell lung cancer[J].Journal of Tianjin Medical University,2018,24(04):415.
[5]董傲然,张家丽,任秀宝,等.促胃泌素释放肽前体对小细胞肺癌的诊断价值[J].天津医科大学学报,2019,25(03):234.
　DONG Ao-ran,ZHANG Jia-li,REN Xiu-bao,et al.Diagnosis value of pro-gastrin-releasing peptide precursor for small cell lung cancer[J].Journal of Tianjin Medical University,2019,25(04):234.
[6]胡 雪 综 述,张新伟 审 校.小细胞肺癌合并低钠血症的研究进展[J].天津医科大学学报,2019,25(04):422.
[7]孙基峰,罗 婧,徐利明,等.广泛期小细胞肺癌肝转移治疗模式探讨[J].天津医科大学学报,2019,25(06):577.
　SUN Ji-feng,LUO Jing,XU Li-ming,et al.Discussion on the treatment mode of liver metastasis in patients with extensive small cell lung cancer[J].Journal of Tianjin Medical University,2019,25(04):577.
[8]杨沛轩,农育新,陈闽霞,等.手术对广泛期小细胞肺癌患者生存的影响：基于SEER数据库的倾向得分匹配分析[J].天津医科大学学报,2021,27(01):36.
　YANG Pei-xuan,NONG Yu-xin,CHEN Min-xia,et al.Effect of surgery on survival in patients with extensive small cell lung cancer:a SEER database-based propensity scores matching analysis[J].Journal of Tianjin Medical University,2021,27(04):36.

备注/Memo

备注/Memo:

作者简介 赵军华（1990-），女，硕士在读，研究方向：肿瘤学（放射治疗学）；通信作者：袁智勇，E-mail：Zhiyong0524@163.com。

常用功能

更新日期/Last Update: 2019-08-28